

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request
Ein Cyf / Our Ref: 23-A-019

You asked:

1. How many of the following intra-vitreous injections/implants has your Health Board administered in the four-month period from September to December 2022:

- Aflibercept - 1987
- Bevacizumab - 0
- Brolucizumab - 0
- Dexamethasone - 68
- Faricimab - 31
- Ranibizumab – Lucentis - 9
- Ranibizumab – Ongavia - 0

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2022.

Number of Injections/Implants: September - December 2022

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	1931	48	8
Bevacizumab	0	0	0
Brolucizumab	0	0	0
Dexamethasone	0	68	0
Faricimab	31	0	0
Ranibizumab - Lucentis	9	0	0



Ranibizumab - Ongavia	0	0	0
-----------------------	---	---	---

